412 related articles for article (PubMed ID: 26428226)
1. iPSC-based drug screening for Huntington's disease.
Zhang N; Bailus BJ; Ring KL; Ellerby LM
Brain Res; 2016 May; 1638(Pt A):42-56. PubMed ID: 26428226
[TBL] [Abstract][Full Text] [Related]
2. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells.
Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H
Mol Brain; 2012 May; 5():17. PubMed ID: 22613578
[TBL] [Abstract][Full Text] [Related]
3. Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy.
Liu L; Huang JS; Han C; Zhang GX; Xu XY; Shen Y; Li J; Jiang HY; Lin ZC; Xiong N; Wang T
Mol Neurobiol; 2016 Dec; 53(10):6698-6708. PubMed ID: 26659595
[TBL] [Abstract][Full Text] [Related]
4. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient.
Chae JI; Kim DW; Lee N; Jeon YJ; Jeon I; Kwon J; Kim J; Soh Y; Lee DS; Seo KS; Choi NJ; Park BC; Kang SH; Ryu J; Oh SH; Shin DA; Lee DR; Do JT; Park IH; Daley GQ; Song J
Biochem J; 2012 Sep; 446(3):359-71. PubMed ID: 22694310
[TBL] [Abstract][Full Text] [Related]
5. Recent Overview of the Use of iPSCs Huntington's Disease Modeling and Therapy.
Csobonyeiova M; Polak S; Danisovic L
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32213859
[TBL] [Abstract][Full Text] [Related]
6. Cellular Models: HD Patient-Derived Pluripotent Stem Cells.
Geater C; Hernandez S; Thompson L; Mattis VB
Methods Mol Biol; 2018; 1780():41-73. PubMed ID: 29856014
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
Cho IK; Yang B; Forest C; Qian L; Chan AWS
PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
[TBL] [Abstract][Full Text] [Related]
8. Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity.
Tousley A; Kegel-Gleason KB
J Huntingtons Dis; 2016 Jun; 5(2):99-131. PubMed ID: 27372054
[TBL] [Abstract][Full Text] [Related]
9. Modeling Huntington's disease with induced pluripotent stem cells.
Kaye JA; Finkbeiner S
Mol Cell Neurosci; 2013 Sep; 56():50-64. PubMed ID: 23459227
[TBL] [Abstract][Full Text] [Related]
10. Progerin-Induced Transcriptional Changes in Huntington's Disease Human Pluripotent Stem Cell-Derived Neurons.
Cohen-Carmon D; Sorek M; Lerner V; Divya MS; Nissim-Rafinia M; Yarom Y; Meshorer E
Mol Neurobiol; 2020 Mar; 57(3):1768-1777. PubMed ID: 31834602
[TBL] [Abstract][Full Text] [Related]
11. Modeling Huntington׳s disease with patient-derived neurons.
Mattis VB; Svendsen CN
Brain Res; 2017 Feb; 1656():76-87. PubMed ID: 26459990
[TBL] [Abstract][Full Text] [Related]
12. Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons.
Nekrasov ED; Vigont VA; Klyushnikov SA; Lebedeva OS; Vassina EM; Bogomazova AN; Chestkov IV; Semashko TA; Kiseleva E; Suldina LA; Bobrovsky PA; Zimina OA; Ryazantseva MA; Skopin AY; Illarioshkin SN; Kaznacheyeva EV; Lagarkova MA; Kiselev SL
Mol Neurodegener; 2016 Apr; 11():27. PubMed ID: 27080129
[TBL] [Abstract][Full Text] [Related]
13. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.
An MC; Zhang N; Scott G; Montoro D; Wittkop T; Mooney S; Melov S; Ellerby LM
Cell Stem Cell; 2012 Aug; 11(2):253-63. PubMed ID: 22748967
[TBL] [Abstract][Full Text] [Related]
14. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.
Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692
[TBL] [Abstract][Full Text] [Related]
15. Immortalized striatal precursor neurons from Huntington's disease patient-derived iPS cells as a platform for target identification and screening for experimental therapeutics.
Akimov SS; Jiang M; Kedaigle AJ; Arbez N; Marque LO; Eddings CR; Ranum PT; Whelan E; Tang A; Wang R; DeVine LR; Talbot CC; Cole RN; Ratovitski T; Davidson BL; Fraenkel E; Ross CA
Hum Mol Genet; 2021 Nov; 30(24):2469-2487. PubMed ID: 34296279
[TBL] [Abstract][Full Text] [Related]
16. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes.
HD iPSC Consortium
Cell Stem Cell; 2012 Aug; 11(2):264-78. PubMed ID: 22748968
[TBL] [Abstract][Full Text] [Related]
17. Induced Pluripotent HD Monkey Stem Cells Derived Neural Cells for Drug Discovery.
Kunkanjanawan T; Carter R; Ahn KS; Yang J; Parnpai R; Chan AWS
SLAS Discov; 2017 Jul; 22(6):696-705. PubMed ID: 28027448
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic alterations mediate iPSC-induced normalization of DNA repair gene expression and TNR stability in Huntington's disease cells.
Mollica PA; Zamponi M; Reid JA; Sharma DK; White AE; Ogle RC; Bruno RD; Sachs PC
J Cell Sci; 2018 Jul; 131(13):. PubMed ID: 29898922
[TBL] [Abstract][Full Text] [Related]
19. Generation of induced pluripotent stem cell line ICGi018-A from peripheral blood mononuclear cells of a patient with Huntington's disease.
Malakhova AA; Grigor'eva EV; Malankhanova TB; Pavlova SV; Valetdinova KR; Abramycheva NY; Vetchinova AS; Illarioshkin SN; Zakian SM
Stem Cell Res; 2020 Apr; 44():101743. PubMed ID: 32179492
[TBL] [Abstract][Full Text] [Related]
20. Generation of an induced pluripotent stem cell line from a Huntington's disease patient with a long HTT-PolyQ sequence.
Miller DC; Lisowski P; Genehr C; Wanker EE; Priller J; Prigione A; Diecke S
Stem Cell Res; 2023 Apr; 68():103056. PubMed ID: 36863131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
